株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リンパ浮腫診断の世界市場の予測 ~2024年:リンパシンチグラフィ・MRI・近赤外蛍光画像・超音波

Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers): Global Forecasts to 2024

発行 MarketsandMarkets 商品コード 915082
出版日 ページ情報 英文 166 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
リンパ浮腫診断の世界市場の予測 ~2024年:リンパシンチグラフィ・MRI・近赤外蛍光画像・超音波 Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers): Global Forecasts to 2024
出版日: 2019年10月25日 ページ情報: 英文 166 Pages
概要

世界のリンパ浮腫診断の市場は予測期間中7.4%のCAGR (年間複合成長率) で推移し、2019年の2400万米ドルから、2024年には3500万米ドルの規模に成長すると予測されています。癌・リンパ浮腫の有病率の拡大、画像診断の技術的進歩、官民組織による投資・資金投入・助成金の増加などの要因が同市場の成長を推進しています。しかし一方で、システムの高コスト性、放射性医薬品の短い半減期、ヘリウム供給の不足などの課題がさらなる成長の障壁となる見通しです。

当レポートでは、世界のリンパ浮腫診断の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、技術・疾患タイプ・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

915082_3_FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE LYMPHEDEMA DIAGNOSTICS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
    • 課題

第6章 リンパ浮腫診断市場の分析・予測:技術別

  • イントロダクション
  • リンパシンチグラフィ
  • MRI
  • 超音波画像
  • CT
  • X線リンパ造影
  • バイオインピーダンス分析
  • 近赤外蛍光画像

第7章 リンパ浮腫診断市場の分析・予測:疾患タイプ別

  • イントロダクション
  • 炎症性疾患
  • 心血管疾患
  • その他

第8章 リンパ浮腫診断市場の分析・予測:エンドユーザー別

  • イントロダクション
  • 病院
  • 診断センター
  • 研究・学術機関
  • その他

第9章 リンパ浮腫診断市場の分析・予測:地域・主要国別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合環境

  • イントロダクション
  • 企業ランキング
  • 競合シナリオ
  • ベンダーダイブ分析

第11章 企業プロファイル

  • GE HEALTHCARE
  • SIEMENS HEALTHINEERS (SIEMENS GROUP)
  • PHILIPS
  • キヤノン
  • 島津製作所
  • STRYKER CORPORATION
  • FLUOPTICS
  • UNITED IMAGING HEALTHCARE CO., LTD.
  • 日立
  • ESAOTE SPA
  • NEUSOFT CORPORATION
  • MINDRAY MEDICAL INTERNATIONAL LIMITED (EXCELSIOR UNION, LTD.)
  • MITAKA USA, INC.
  • CURADEL, LLC
  • IMPEDIMED LIMITED
  • その他

第12章 付録

図表

LIST OF TABLES

  • TABLE 1: TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING SYSTEMS
  • TABLE 2: KEY INVESTMENTS BY GOVERNMENT BODIES IN THE DIAGNOSTIC IMAGING MARKET
  • TABLE 3: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 4: COMPARISON OF DIAGNOSTIC IMAGING TESTS FOR LYMPHEDEMA
  • TABLE 5: LYMPHOSCINTIGRAPHY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 6: LYMPHOSCINTIGRAPHY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 7: MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 8: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 9: ULTRASOUND IMAGING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 11: COMPUTED TOMOGRAPHY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 12: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 13: X-RAY LYMPHOGRAPHY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 14: X-RAY LYMPHOGRAPHY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 15: BIOIMPEDANCE ANALYSIS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16: BIOIMPEDANCE ANALYSIS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 17: NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 18: NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19: NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 20: ICG LYMPHOGRAPHY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 21: ICG LYMPHOGRAPHY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 22: FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23: FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 25: LYMPHEDEMA DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 26: LYMPHEDEMA DIAGNOSTICS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27: LYMPHEDEMA DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 28: LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 29: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 30: LYMPHEDEMA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31: LYMPHEDEMA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 32: LYMPHEDEMA DIAGNOSTICS MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 33: LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 34: LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 35: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 36: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 37: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 39: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 40: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 41: US: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 42: US: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 43: US: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 44: US: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 45: CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 46: CANADA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 47: CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 48: CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 49: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 50: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 51: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 52: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 53: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 54: GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 55: GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 56: GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 57: GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 58: FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 59: FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 60: FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 61: FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 62: UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 63: UK: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 64: UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 65: UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 66: ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 67: ROE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 68: ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 69: ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 70: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 71: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 72: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 74: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 75: CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 76: CHINA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 77: CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 78: CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 79: JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 80: JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81: JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 82: JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 83: INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 84: INDIA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85: INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 86: INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 87: ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 88: ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89: ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 90: ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 91: ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 92: ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 93: ROW: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 94: ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 96: LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 97: LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 98: LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 99: LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 100: MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 101: MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 102: MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017-2024 (USD MILLION)
  • TABLE 103: MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 104: PRODUCT LAUNCHES, ENHANCEMENTS, & APPROVALS
  • TABLE 105: PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
  • TABLE 106: ACQUISITIONS
  • TABLE 107: EXPANSIONS

LIST OF FIGURES

  • FIGURE 1: LYMPHEDEMA DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARIES: GLOBAL LYMPHEDEMA DIAGNOSTICS MARKET
  • FIGURE 4: RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5: MARKET SIZE ESTIMATION: LYMPHEDEMA DIAGNOSTICS MARKET
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: GEOGRAPHIC ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019
  • FIGURE 9: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE LYMPHEDEMA DIAGNOSTICS MARKET
  • FIGURE 11: RISING PREVALENCE OF LYMPHEDEMA-A MAJOR FACTOR DRIVING THE MARKET FOR LYMPHEDEMA DIAGNOSTICS
  • FIGURE 12: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, IN 2019
  • FIGURE 13: NEAR-INFRARED FLUORESCENCE IMAGING TO REGISTER THE HIGHEST GROWTH IN THE LYMPHEDEMA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: ICG LYMPHOGRAPHY SEGMENT WILL CONTINUE TO DOMINATE THE NEAR-INFRARED FLUORESCENCE IMAGING MARKET IN 2024
  • FIGURE 15: CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 16: LYMPHEDEMA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 18: EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 19: ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 20: GE HEALTHCARE HELD THE LEADING POSITION IN THE LYMPHEDEMA DIAGNOSTICS MARKET IN 2018
  • FIGURE 21: LYMPHEDEMA DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2018
  • FIGURE 22: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 23: SIEMENS AG: COMPANY SNAPSHOT
  • FIGURE 24: PHILIPS: COMPANY SNAPSHOT
  • FIGURE 25: CANON, INC.: COMPANY SNAPSHOT
  • FIGURE 26: SHIMADZU CORPORATION: COMPANY SNAPSHOT
  • FIGURE 27: STRYKER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 28: HITACHI, LTD.: COMPANY SNAPSHOT
  • FIGURE 29: NEUSOFT CORPORATION: COMPANY SNAPSHOT
  • FIGURE 30: IMPEDIMED LIMITED: COMPANY SNAPSHOT
目次
Product Code: MD 7408

"The lymphedema diagnostics market is projected to grow at a CAGR of 7.4% during the forecast period."

The global lymphedema diagnostics market is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%. The major factors driving the growth of this market include the increasing global prevalence of cancer and lymphedema; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, and the limited supply of helium are expected to hinder the growth of this market.

"The lymphoscintigraphy segment accounted for the largest market share in 2018."

Based on technology, the lymphedema diagnostics market is segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.

"The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018."

On the basis of disease type, the lymphedema diagnostics market is segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.

"Europe to account for the second-largest share of the global market in 2019."

The lymphedema diagnostics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is expected to account for the second-largest share of the global lymphedema diagnostics market in 2019. The rising incidence of chronic diseases and injuries, growing demand for early diagnosis and treatment, technological advancements, product launches, and increasing government and public-private investments for developing novel diagnostic imaging modalities are the major factors driving market growth in Europe.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (25%), Tier 2 (30%), and Tier 3 (42%)
  • By Designation: C-level (26%), Director-level (30%), and Others (44%)
  • By Region: North America (34%), Europe (26%), APAC (23%), and RoW (17%)

The major players in the market include: GE Healthcare (US), Philips (Netherlands), Siemens Healthineers (Germany), Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).

Research Coverage:

This report studies the lymphedema diagnostics market based on technology, disease type, end user, and region. The report also studies factors (such as drivers and restraints) affecting market growth. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 PRIMARY RESEARCH VALIDATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS
    • 2.4.1 LIMITATIONS
    • 2.4.2 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 LYMPHEDEMA DIAGNOSTICS: MARKET OVERVIEW
  • 4.2 REGIONAL ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE (2019)
  • 4.3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
  • 4.4 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • 4.5 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing global prevalence of lymphedema
      • 5.2.1.2 Growing global prevalence of cancer
      • 5.2.1.3 Technological advancements and adoption of newer diagnostic modalities
      • 5.2.1.4 Increasing investments, funds, and grants by public-private organizations
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of diagnostic imaging systems
      • 5.2.2.2 Short half-life of radiopharmaceuticals
      • 5.2.2.3 Limited supply of helium
      • 5.2.2.4 Increasing adoption of refurbished diagnostic imaging systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Hospital budget cuts

6 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
  • 6.2 LYMPHOSCINTIGRAPHY
    • 6.2.1 LYMPHOSCINTIGRAPHY IS RAPIDLY DEVELOPING TO BE THE FIRST-LINE IMAGING MODALITY FOR LYMPHEDEMA DIAGNOSTICS
  • 6.3 MAGNETIC RESONANCE IMAGING
    • 6.3.1 MAGNETIC RESONANCE IMAGING FINDS MAJOR APPLICATIONS IN LYMPHEDEMA TREATMENT PLANNING
  • 6.4 ULTRASOUND IMAGING
    • 6.4.1 ULTRASOUND IMAGING HAS THE POTENTIAL TO DETERMINE TISSUE CHANGES CONSISTENT WITH DIFFERENT STAGES OF LYMPHEDEMA
  • 6.5 COMPUTED TOMOGRAPHY
    • 6.5.1 HIGH COST OF COMPUTED TOMOGRAPHY TO LIMIT MARKET GROWTH
  • 6.6 X-RAY LYMPHOGRAPHY
    • 6.6.1 INVASIVE NATURE & RISK OF RADIATION EXPOSURE ARE EXPECTED TO HAMPER MARKET GROWTH
  • 6.7 BIOIMPEDANCE ANALYSIS
    • 6.7.1 LACK OF AWARENESS ABOUT BIOIMPEDANCE ANALYSIS IS LIMITING THE GROWTH OF THIS SEGMENT
  • 6.8 NEAR-INFRARED FLUORESCENCE IMAGING
    • 6.8.1 ICG LYMPHOGRAPHY
      • 6.8.1.1 ICG lymphography offers a powerful tool for efficiently diagnosing various stages of lymphedema
    • 6.8.2 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY
      • 6.8.2.1 Fluorescein sodium microlymphangiography is limited to visualizing only initial capillaries

7 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 7.1 INTRODUCTION
  • 7.2 CANCER
    • 7.2.1 ONE IN THREE CANCER-TREATED PATIENTS DEVELOP LYMPHEDEMA
  • 7.3 INFLAMMATORY DISEASES
    • 7.3.1 GROWING PREVALENCE OF INFLAMMATORY CONDITIONS TO DRIVE MARKET GROWTH
  • 7.4 CARDIOVASCULAR DISEASE
    • 7.4.1 GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS TO DRIVE THE ADOPTION OF LYMPHEDEMA DIAGNOSTIC TOOLS
  • 7.5 OTHER DISEASES

8 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 THE LARGE NUMBER OF LYMPHEDEMA DIAGNOSTIC PROCEDURES PERFORMED IN HOSPITALS TO DRIVE MARKET GROWTH
  • 8.3 DIAGNOSTIC CENTERS
    • 8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
  • 8.4 RESEARCH & ACADEMIC INSTITUTES
    • 8.4.1 BUDGETARY RESTRICTIONS OF RESEARCHERS ARE LIMITING THE ADOPTION OF HIGH-END LYMPHEDEMA DIAGNOSTIC TECHNOLOGIES
  • 8.5 OTHER END USERS

9 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 The US dominated the North American market in 2018
    • 9.2.2 CANADA
      • 9.2.2.1 Dearth of radiologists is restricting market growth in Canada
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany accounts for the largest share of the European market
    • 9.3.2 FRANCE
      • 9.3.2.1 Uncertainties with regard to the pricing strategy of diagnostic companies to limit market growth in France to a certain extent
    • 9.3.3 UK
      • 9.3.3.1 Rising diagnostic imaging procedural volumes indicate strong growth in the UK market
    • 9.3.4 ROE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
      • 9.4.1.1 Rising disease incidence, increasing procedural volumes, and growth in the geriatric population have contributed to market growth in China
    • 9.4.2 JAPAN
      • 9.4.2.1 Japan's well-established and well-equipped healthcare system ensures demand for and easy access to diagnostic imaging
    • 9.4.3 INDIA
      • 9.4.3.1 Growing incidence of lymphatic filariasis is a key contributor to market growth
    • 9.4.4 ROAPAC
  • 9.5 REST OF THE WORLD
    • 9.5.1 LATIN AMERICA
      • 9.5.1.1 Latin America holds the largest share of the RoW market
    • 9.5.2 MIDDLE EAST & AFRICA
      • 9.5.2.1 Growing geriatric population & disease prevalence are driving growth in MEA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 RANKING OF PLAYERS, 2018
  • 10.3 COMPETITIVE SCENARIO
  • 10.4 VENDOR DIVE OVERVIEW
  • 10.5 VENDOR INCLUSION CRITERIA
  • 10.6 VENDOR DIVE
    • 10.6.1 VISIONARY LEADERS
    • 10.6.2 INNOVATORS
    • 10.6.3 DYNAMIC DIFFERENTIATORS
    • 10.6.4 EMERGING COMPANIES

11 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1 GE HEALTHCARE
  • 11.2 SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS GROUP)
  • 11.3 PHILIPS
  • 11.4 CANON, INC.
  • 11.5 SHIMADZU CORPORATION
  • 11.6 STRYKER CORPORATION
  • 11.7 FLUOPTICS
  • 11.8 UNITED IMAGING HEALTHCARE CO., LTD.
  • 11.9 HITACHI, LTD.
  • 11.10 ESAOTE SPA
  • 11.11 NEUSOFT CORPORATION
  • 11.12 MINDRAY MEDICAL INTERNATIONAL LIMITED (A SUBSIDIARY OF EXCELSIOR UNION, LTD.)
  • 11.13 MITAKA USA, INC.
  • 11.14 CURADEL, LLC
  • 11.15 IMPEDIMED LIMITED
  • 11.16 OTHER COMPANIES

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
Back to Top